Class / Patent application number | Description | Number of patent applications / Date published |
514217010 | 3-Benzazepines (including hydrogenated) | 84 |
20080234252 | Compounds Useful in Therapy - Compounds of formula (I), | 09-25-2008 |
20080255092 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists - The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R″R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification. | 10-16-2008 |
20080255093 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS - The present invention is drawn to combinations of pharmaceutical agents having similar chemical and/or pharmacological properties, wherein the combinations maximize the therapeutic effect of the drug while minimizing their adverse effects. The methods and compositions of the invention are particularly useful in the treatment of obesity and related conditions which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) or bupropion in combination with an anti-epileptic agent (e.g., topiramate, zonisamide), CB1 antagonists (e.g., rimonabant), or a 5HT | 10-16-2008 |
20080269196 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists - The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification. | 10-30-2008 |
20080269197 | AROMATIC SULFONES AND THEIR MEDICAL USE - The invention provides compounds of formula (I): | 10-30-2008 |
20080312213 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor - Compounds of formula (I) or a salt thereof are disclosed: | 12-18-2008 |
20090005361 | Combination of Organic Compounds - The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising a therapeutic agent acting on the renin-angiotensin system (RAS) or a pharmaceutically acceptable salt thereof and comprising at least one CB1 antagonist, or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use of such a combination for the prevention of, delay of progression of, treatment of diseases and disorders that may be modulated by action on the renin-angiotensin system (RAS), appetency disorders or substance abuse disorders. | 01-01-2009 |
20090069296 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 03-12-2009 |
20090099155 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS - The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT | 04-16-2009 |
20090105224 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor - The invention relates to tetrahydrobenzazepines of the general formula I | 04-23-2009 |
20090105225 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists - The present invention relates to compounds of formula (I), | 04-23-2009 |
20090105226 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. | 04-23-2009 |
20090118260 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN - The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): | 05-07-2009 |
20090143363 | Deuterated lorcaserin - This invention relates to novel compounds that are 3-benzazepine derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 3-benzazepine derivatives that are derivatives of lorcaserin. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a 5-HT | 06-04-2009 |
20090163475 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE - The present invention relates to a novel polymorphic form of 7-[4-(4-chlorobenzyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepinium maleate and a pharmaceutically acceptable solvate thereof, pharmaceutical formulation, process for its preparation and its use in medicine, in particular its use as an antipsychotic agent. | 06-25-2009 |
20090239845 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS - Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R | 09-24-2009 |
20090318423 | Ion Channel Modulators & Uses Thereof - Compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula (1) wherein A and B are CH | 12-24-2009 |
20100004223 | Crystalline Forms Of (R)-8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine Hydrochloride - The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same, preparations, and uses thereof. | 01-07-2010 |
20100069362 | Thienopyrimidone compound - The present invention relates to a compound represented by the formula: | 03-18-2010 |
20100120747 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY - The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. | 05-13-2010 |
20100120748 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL - The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described. | 05-13-2010 |
20100152165 | CARBOXYLIC ACID DERIVATIVES - [Problem] To provide a pharmaceutical, particularly a compound which can be used as an insulin secretion promoter or a preventive or therapeutic agent for diabetes mellitus and the like diseases in which GPR40 is concerned. | 06-17-2010 |
20100173894 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES - The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders. | 07-08-2010 |
20100197664 | NOVEL B1-ANTAGONISTS - Disclosed are compounds of the formula I | 08-05-2010 |
20100273777 | Compounds for Modulating TRPV3 Function - The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. | 10-28-2010 |
20100273778 | TREATMENT OF OSTEOARTHRITIS PAIN - This invention discloses a method of treatment of osteoarthritis pain by administration of a histamine H | 10-28-2010 |
20100331312 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - Amide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as excessive daytime sleepiness, narcolepsy, shift-work sleep disorder, drowsiness as a side effect from a medication, maintenance of vigilance to aid in the completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like. | 12-30-2010 |
20110039827 | Substituted hydroxamic acids and uses thereof - This invention provides compounds of formula (I): | 02-17-2011 |
20110130383 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases - Use of compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula (1) wherein A and B are CH | 06-02-2011 |
20110130384 | AMIDE COMPOUND - The present invention aims to provide a prophylactic or therapeutic agent for schizophrenia and the like, containing the compound of the present invention having a GPR52 agonist activity. A compound represented by the following formula (I) or a salt thereof: | 06-02-2011 |
20110130385 | Bicyclic Heterocylic Derivatives and Methods of Use - The present invention relates to novel bicyclic heterocycle derivatives, pharmaceutical compositions comprising the bicyclic heterocycle derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R | 06-02-2011 |
20110152250 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF - Compounds that are antagonists of the VR1 receptor, having formula (I) | 06-23-2011 |
20110166125 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS - The present invention relates to new substituted prolinamides of general formula (I) wherein D, Y, A, B, R | 07-07-2011 |
20110269745 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS - The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification. | 11-03-2011 |
20120028961 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist - The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT | 02-02-2012 |
20120094979 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS - Thiazole or thiadizaloe derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed. | 04-19-2012 |
20120135982 | 5HT2c RECEPTOR MODULATORS - The present invention relates to novel compounds of Formula (I): | 05-31-2012 |
20120184533 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY - Compounds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer. | 07-19-2012 |
20120232061 | NOVEL COMPOUNDS - A compound of formula (I): | 09-13-2012 |
20120252786 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE - The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions whose use includes the treatment of obesity. | 10-04-2012 |
20120252787 | ADMINISTRATION OF AN ANTI-OBESITY COMPOUND TO INDIVIDUALS WITH RENAL IMPAIRMENT - The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. | 10-04-2012 |
20120252788 | 5HT2C RECEPTOR MODULATORS - The present invention relates to novel compounds of Formula (I): | 10-04-2012 |
20120258957 | HETEROCYCLIC DERIVATIVES - The present invention relates to a heterocyclic derivative according to formula I | 10-11-2012 |
20120264743 | CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL-2,3,4,5-THTRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE - The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same and uses thereof. | 10-18-2012 |
20130012498 | 5HT2C RECEPTOR MODULATORS - The present invention relates to novel compounds of Formula (I): | 01-10-2013 |
20130018042 | Toll-Like Receptor Agonist Formulations and Their Use - The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin. | 01-17-2013 |
20130059838 | SUBSTITUTED N-HETEROARYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-heteroaryl tetrahydro-isoquinoline derivatives of formula (I). | 03-07-2013 |
20130085134 | QUINOXALINE COMPOUND - Quinoxaline compounds of formula (I) have a PDE9-inhibiting action and are useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like. | 04-04-2013 |
20130123241 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (I) wherein HET is a group selected from among formulas (IIa) (IIb) (IIc) (IId) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD and pain diseases. | 05-16-2013 |
20130143870 | NOVEL COMPOUNDS - This invention relates to compounds of formula I | 06-06-2013 |
20130158013 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS - Processes and intermediates for preparing salts of the 5-HT | 06-20-2013 |
20130172322 | BENZAZEPINE DERIVATIVES USEFUL FOR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES - The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders. | 07-04-2013 |
20130217676 | 5HT2C RECEPTOR MODULATORS - The present invention relates to novel compounds of Formula (I): | 08-22-2013 |
20130217677 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE - The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions whose use includes the treatment of obesity. | 08-22-2013 |
20130267500 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL - Uses of 5-HT | 10-10-2013 |
20130310369 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS - Salts of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine with optically active acids, and pharmaceutical compositions comprising them that are useful for, inter alia, weight management. | 11-21-2013 |
20130317010 | TETRAHYDROISOQUINOLINE DERIVATIVE - To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT | 11-28-2013 |
20140005177 | PYRIDINYL- AND PYRAZINYL-METHYLOXY-ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | 01-02-2014 |
20140051684 | CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE - The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same and uses thereof. | 02-20-2014 |
20140121201 | REGULATORY NETWORK FOR Th17 SPECIFICATION AND USES THEREOF - Screening assays and methods of using same for screening to identify modulator agents or compounds that affect Th17 cell specification are described herein. Pharmaceutical compositions comprising agents or compounds that modulate Th17 cell specification are also encompassed. Methods for modulating Th17 cell specification using agents identified using assays described herein in pharmaceutical compositions are also envisioned. Such pharmaceutical compositions are useful for treating inflammatory conditions and autoimmune diseases associated with Th17 cell mediated pathology. | 05-01-2014 |
20140148442 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS - Salts of the 5-HT | 05-29-2014 |
20140171418 | Antibacterial homopiperidinyl substituted 3,4 dihydro 1H[1,8]naphthyridinones - The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds. | 06-19-2014 |
20140187538 | LORCASERIN HYDROCHLORIDE - The present invention relates to amorphous lorcaserin hydrochloride; amorphous solid dispersion comprising lorcaserin hydrochloride and one or more pharmaceutically acceptable carries; processes for preparation thereof; pharmaceutical compositions comprising amorphous lorcaserin hydrochloride and one or more pharmaceutically acceptable carries. | 07-03-2014 |
20140213579 | METHOD OF WEIGHT MANAGEMENT - Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual. | 07-31-2014 |
20140296212 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS - The present invention provides compounds of formula I: | 10-02-2014 |
20140315893 | 1,4- DIHYDROPYRIDINE DERIVATIVES WITH HSP MODULATING ACTIVITY - The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R | 10-23-2014 |
20150025063 | Antiparkinsonian Action of Phenylisopropylamines - A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease. | 01-22-2015 |
20150080380 | Therapeutic Uses - This invention relates to novel therapeutic uses for compounds which are inverse agonists of the H3 receptor. In particular this invention relates to therapeutic use of these compounds in the treatment of Multiple Sclerosis. | 03-19-2015 |
20150087634 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS - The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): | 03-26-2015 |
20150141407 | N-Aryl Unsaturated Fused Ring Tertiary Amine Compounds, Preparation Method and Anti-Tumor Applications Thereof - The present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, its preparation method, a pharmaceutical composition comprising the compound, and its use in manufacture of a medicament for treatment of a disease or disorder, wherein R | 05-21-2015 |
20160009654 | CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL- 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE | 01-14-2016 |
20160031820 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 02-04-2016 |
20160089378 | TREATMENT OF OSTEOARTHRITIS PAIN - This invention discloses a method of treatment of osteoarthritis pain by administration of a histamine H | 03-31-2016 |
20160151381 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | 06-02-2016 |
20160194718 | Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators | 07-07-2016 |
20160250223 | 5HT2C RECEPTOR MODULATORS | 09-01-2016 |
514217020 | Benzene ring bonded directly to ring carbon of the seven-membered hetero ring | 8 |
20090156581 | Aminergic pharmaceutical compositions and methods - Pharmaceutical compositions and method using aminergic compounds and complement compounds. Compositions are provided comprising: (a) a subefficacious amount of a non-adrenergic aminergic compound or of an adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Methods are also provided comprising the administration of: (a) a low dose of a non-adrenergic aminergic compound or of any adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Non-adrenergic aminergic compounds can comprise a histaminergic, dopaminergic, muscarinergic, serotoninergic, octopaminergic, or trace aminergic compound. Complement compounds include ascorbates, opioids, polycarboxylic acid chelators, resveratrols, cysteines, substituted derivatives and analogs thereof, and mixtures thereof. Preferred complements include ascorbates, particularly ascorbic acid. Methods include the treatment of: neurological and neural disorders; mood and behavior disorders; cardiac, vascular, and cardiovascular disorders; hypertension, headache; respiratory disorders; gastrointestinal disorders; obesity; asthma, allergy; smooth muscle contraction disorders; nasal or nasopharyngeal conditions; genitourinary disorders; ocular disorders, glaucoma; hormone- or neurotransmitter-release or -secretion disorders. | 06-18-2009 |
20100286124 | PROP-2-YN-1-AMINE INHIBITORS OF MONOAMINE OXIDASE TYPE B - The present invention relates to new prop-2-yn-1-amine inhibitors of monoamine oxidase type B activity, pharmaceutical compositions thereof, and methods of use thereof. | 11-11-2010 |
20120058992 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF ANGIOGENESIS - The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate angiogenesis for treating said disease. | 03-08-2012 |
20130338145 | Method for Mediating Dopamine Receptor-Driven Reacidification of Lysosomal pH - Provided is a method of treating or preventing age-related macular degeneration (AMD) or Stargardt's disease in a patient subject to, or symptomatic of the disease, whereby normal lysosomal pH (pH | 12-19-2013 |
20140051685 | THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDIABETES - The present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. | 02-20-2014 |
20140249136 | Parenteral Formulations of Dopamine Agonists - This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics. | 09-04-2014 |
20150065489 | Substituted Quinolines and Their Use As Medicaments - Disclosed are substituted quinolines of formula 1 | 03-05-2015 |
20160158247 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors - This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents. | 06-09-2016 |